News

Moberg Pharma will acquire three OTC brands from Bayer HealthCare.

GSK forms the Oncology Clinical and Translational Consortium, a scientific research network comprised of six international cancer centers.

Phillips-Medisize announces the expansion to its Kontiolahti, Finland site.

BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.

GlaxoSmithKline plans to expand its facilities in Ware and Worthing in the United Kingdom and will build a new facility for manufacturing innovation.

The University of Missouri's Department of Biochemistry and ABC Laboratories announce industry internship program.

FDA details efforts to evaluate potential risks from use of nanomaterials in drug products and discuss analytical considerations, impact on stability, safety, and toxicology effects.

Roche and Prothena sign deal worth up to $600 million to develop and commercialize antibodies that target alpha-synuclein.

Harlan announces Hiroharu Okochi as president of Harlan Japan.

Johnson&Johnson will open a network of partnering offices across the UK.

AstraZeneca will receive $76 million in damages from Apotex Corp., Apotex, and Torpharm.

Shire's United States subsidiary enters supply agreement for Adderall XR.

Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.

OGD is under pressure to improve review operations.

ScinoPharm completes new API manufacturing plant in Changshu, China.

Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).

Octapharma and Pfizer form an agreement for the future marketing and commercialization of human prothrombin complex concentrate.

Researchers at Massachusetts recently reported on the development of a drug-eluting contact lens designed to provide prolonged delivery of the glaucoma medication, latanoprost.

Novasep expands its presence in India with the opening of Novasep Process Engineering Services, a part of its industrial business unit.

GDUFA is off to a good start from a facility inspection perspective, but there are storm clouds on the horizon.

Standards for ferrules and cap overseals focus on explicit warnings.

FDA cites cGMP violations and data-integrity issues and raises concerns over the company's ability to implement a robust and sustainable quality system.

Alvotech plans investment in biosimilars portfolio and manufacturing facility.

The flexible biomanufacturing system uses single-use technology.

Jill E. Sackman, D.V.M., PhD, senior consultant at Numerof & Associates, Inc. discusses the market forces impacting biopharmaceutical manufacturing

PharmaCheck, a portable tool designed to detect poor-quality medicines, has been selected by Scientific American as one of the magazine?s World Changing Ideas of 2013.

LSNE appoints Shawn Cain as COO, a new position within the company.

Facility in Germany provides space for evaluating continuous pharmaceutical processing equipment.

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

EMA revises its polices on fee reductions for orphan drugs for 2014.